
Leo Mascarenhas MD
Professor, Cedar Sinai Medical Center Director, Pediatric Hematology Oncology Director, Sarcoma Oncology
Join to View Full Profile
8700 Beverly BoulevardNT Suite 4221Los Angeles, CA 90048
Phone+1 310-423-4423
Dr. Mascarenhas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board-certified pediatrician and pediatric hematologist-oncologist academically focused on developmental therapeutics for pediatric and adolescent solid tumors with a particular expertise in bone and soft tissue sarcomas and developmental therapeutics for solid tumors including Wilms tumor and hepatoblastoma. My research interest is to investigate molecular targeted therapy and immunotherapy alone or in combination with chemotherapy in sarcomas and pediatric solid tumors. I have been actively involved in clinical research for more than 25 years with experience in designing and conducting Phase I, Phase II and Phase III clinical trials. I presently serve as the Chair of the Voting Body of the Children’s Oncology Group (COG), the institutional Principal Investigator (PI) for COG at Cedar-Sinai and was the institutional COG PI for 16 years until October 2023 and the PI for the Pediatric Early Phase Clinical Trials Network (PEPCTN) at Children's Hospital Los Angeles until August 2019. I have been the principal investigator on three investigator-initiated institutional Phase I clinical trials, serve/d as the principal investigator, co-principal investigator, co-investigator on several COG Phase II/III clinical trials and lead investigator on four pharma sponsored trials. I also serve as the local principal investigator on Sarcoma Alliance for Research through Collaboration (SARC) clinical trials and other multi- institutional clinical trials that are either consortia-based investigator-initiated or pharmaceutical industry supported. I am committed to improving outcomes for children and adolescents with cancer through clinical research. I am also a committed mentor and educator to peers and colleagues. I have multiple publications in which I have collaborated on with my mentees. I provide education to others to improve outcomes for children with cancer as well as enhance the knowledge and skills of the medical scientific community.
Education & Training
- Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1995 - 1998
- Westchester Medical CenterResidency, Pediatrics, 1992 - 1995
- St. John's Medical CollegeClass of 1991
Certifications & Licensure
- CA State Medical License 1995 - 2026
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsElective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.Leo Mascarenhas, Steven G DuBois, Catherine M Albert, Stefan Bielack, Daniel Orbach
Journal of Clinical Oncology. 2025-04-01 - Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group.Riaz Gillani, David S Shulman, Natalie J DelRocco, Kelly Klega, Ruxu Han
Medrxiv. 2025-01-20 - Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting.Netta Schneller, Najat Daw, Whitney Throckmorton, Elizabeth Mullen, Kylene DeSmith
Pediatric Blood & Cancer. 2025-01-01
Press Mentions
- Drug Safe for Long-Term Use in Kids with Rare Cancer, Study FindsFebruary 4th, 2025
- Children’s Hospital Los Angeles Develops Liquid Biopsy Test for Pediatric Solid TumorsMarch 2nd, 2023
- Children’s Hospital Los Angeles Breakthrough Study with RhabdomyosarcomaSeptember 18th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: